Matching adjusted indirect comparison addresses key questions and limitations associated with previously presented analysis and suggests efficacy advantage of BRUKINSA vs acalabrutinib In this MAIC, ...
Please provide your email address to receive an email when new articles are posted on . Fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, improved survival compared with ...
Please provide your email address to receive an email when new articles are posted on . Time-limited, dual B-cell receptor inhibitor therapy seems promising in treatment-naive and relapsed/refractory ...
Medical experts illustrate the impact of combination therapy for treatment of CLL and SLL. This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Tara ...
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone First and only BTK inhibitor approved for the 1st-line ...
A phase 3, randomized, open-label trial enrolled 535 patients who were randomly assigned 1:1:1 to receive acalabrutinib-obinutuzumab (n = 179), acalabrutinib monotherapy (n = 179), or ...
Combination therapy has potential to be an all-oral, fixed-duration regimen for previously untreated patients with CLL Application is supported by data from the Phase 3 AMPLIFY trial that showed ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of ...
The data presented covered everything from its mainstay acalabrutinib, sold as Calquence, to the eye-catching AZD0120, an ...
Lori A. Leslie, MD: We now have 3 covalent BTK [Bruton tyrosine kinase] inhibitors approved in CLL [chronic lymphocytic leukemia]. We talked a bit about the frontline setting, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback